



Cala Trio™

Cala Trio is the first non-invasive targeted therapy that reduces hand tremors for adults living with Essential Tremor (ET). Prescription therapy is a simple, wrist-worn device that is calibrated to treat a patient’s unique tremor symptoms. When activated, Cala Trio gently stimulates the nerves in the wrist to disrupt the tremulous activity in the brain, without the need for invasive brain surgery or medication. The easy-to-use and effective Cala Trio can be prescribed through an in-person consultation or telemedicine appointment. Therapy is conveniently delivered to the patient’s home, and Cala Health educates patients based on how they learn—phone, video, user portal.

Cala Therapy, now marketed as Cala Trio, achieved statistically significant improvements in symptomatic relief of ET in the treated hand, as measured by validated physician and patient assessment scales and motion sensor data in the PROSPECT Study.



At A Glance

- A wrist-worn neuromodulation therapy for ET that delivers individualized treatment via onboard physiologic sensors with durable electrodes.
- First and only non-invasive prescription therapy that goes directly to the source of tremor and is specifically designed to treat ET.
- Condition is marked by hand tremors that make it difficult, if not impossible, to perform daily activities, including eating, drinking, and writing. Cala Trio therapy puts patients in control of their tremor, without the need for invasive brain surgery or drugs.
- Calibrated to each patient's tremor pattern. When activated, Cala Trio gently stimulates the nerves in the wrist to disrupt the tremulous activity in the brain.
- Received de novo FDA clearance in April 2018 for the transient relief of hand tremors in adults with ET.



The Commercial Model



The vertically integrated, patient centric, commercial model was designed with the patient at the center. It is both connected and responsive to deliver a high-quality Cala Trio experience from access to user feedback



Cala Trio therapy can be conveniently prescribed through an in-office consultation or telemedicine appointment for patients diagnosed with essential tremor



Therapy is conveniently delivered to the patient's home, and Cala Health's Customer Success team educates the patient via phone, video, user portal



Therapy is cloud-connected enabling individual patient insights and ongoing study of tremor to inform future treatments for movement disorders

cala
trio™



Milestones

- 2013**
Cala Health founded
- 2014**
Cala Health initiated proof of concept studies for treating hand tremor in ET
- 2016**
Multicenter randomized controlled trial completed
- 2018**
Cala therapy was FDA cleared for transient relief of hand tremors in adults with ET.

First subject enrolled in **PRO**spective study for **Sym**Ptomatic relief of **Ess**ential tremor with **Cala** Therapy (PROSPECT) [NCT03597100](https://clinicaltrials.gov/ct2/show/study/NCT03597100)
- 2019**
Cala Health commercialized the Cala Trio for ET in the United States.
[Technology Innovations 2019 Best Practices](#)
- 2020**
Tremor and Other Hyperkinetic Movements publishes PROSPECT—the largest therapeutic clinical trial for ET. Data collected from 263 patients from 26 sites using the therapy for 3 months.



@CalaHealth



Cala Health



@CalaHealth



@CalaHealth



Cala-Health-inc